Dan Gasby, a television producer, author, and Alzheimer’s disease advocate, is teaming up with the nonprofit American Brain Foundation (ABF) to support and advance research into brain and nervous system disorders, especially for African-Americans. He’ll undoubtedly be a strong voice on the ABF’s board of directors, to which he was recently appointed.
Cognition Therapeutics has announced the dosing of the first Alzheimer’s patient in a Phase 1b clinical trial of its drug candidate, CT1812, for the treatment of mild to moderate Alzheimer’s disease (AD). CT1812 is a proprietary, first-in-class, orally available, drug-like small molecule designed to displace bound amyloid beta oligomers (molecules thought to be…
Dr. David Satcher, the former U.S. Surgeon General, was named to the Board of Directors of UsAgainstAlzheimers (UsA2), where he will contribute his voice and influence to the non-profit organization as it advocates for greater urgency and action against Alzheimer’s disease. Satcher, who was a four-star admiral in the United States Public Health…
Cure Alzheimer’s Fund, a Massachusetts-based nonprofit dedicated to funding promising research into ways to prevent, slow, or reverse Alzheimer’s disease, has awarded more than $700,000 in research grants in September to scientists working toward those goals. The five newly funded projects brings Cure Alzheimer’s research support for 2016 to more…
A new study by researchers at Rice University in Houston used computer simulations to explore the beginnings of the molecular process that marks the start of Alzheimer’s disease, which is triggered by the aggregation of a common protein called amyloid beta. The Rice investigators are the first to model the energy…
NeuroTherapia, a Cleveland Clinic spin-off biotech company, has received a $1.7 million funding commitment from the Alzheimer’s Drug Discovery Foundation to advance its lead drug candidate NTRX-07 — a selective cannabinoid type 2 (CB2) receptor agonist that can be orally administered — toward human clinical trials. This therapy targets…
Neurotrope BioScience has submitted an amended protocol to the U.S. Food and Drug Administration (FDA) for a Phase 2b clinical trial of its lead product candidate bryostatin-1 for treating advanced Alzheimer’s disease. The company said in a press release that in the original trial protocol, the primary efficacy outcome is…
Quest Diagnostics has announced the release of CogniSense, its digital cognitive assessment tool to assist physicians in diagnosing, assessing, and managing the care of people with cognitive dysfunction. Quest says its design objective for CogniSense was to overcome the various limitations inherent in conventional, paper-based cognitive assessment, such as…
Alzheimer’s disease has been described in medical literature for more than a century, but still has no effective treatments. Now, scientists at the Salk Institute in La Jolla, California, report finding evidence that tetrahydrocannabinol (THC), one of several physiologically active chemical compounds in marijuana, can promote cellular removal of amyloid beta, a toxic…
Results of a new study published in the Journal of Alzheimer’s Disease by a team of researchers at the University of Toronto, Wilfrid Laurier University in Waterloo, Ontario, and the Baycrest Centre in Toronto, Canada, reports the investigators’ assessment of the effect of stimulating…
Get regular updates to your inbox.